HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Public TV Channel Investment Shows UK CBD Market 'Normalizing'

Executive Summary

UK public service TV network Channel 4 says its investment in Cannaray will help bring CBD to the mainstream and shows the country's CBD market is stabilizing.

You may also be interested in...



GSK Signals CBD Interest With Agreement For Potential Australian Launch

GSK will evaluate the launch potential in Australia of a non-prescription CBD product currently being studied as a short-term treatment for sleep disturbances. The firm also has first refusal to negotiate the rights to market the product – developed by Cann Group – in other countries around the world.

Unlisted CBD Products Could Soon Be Removed From UK Shelves, Says FSA

The Food Standards Agency's list of validated and on-hold CBD products will soon see a significant update, says CEO Emily Miles. Those not on the list will be targeted for removal.

UK FSA Admits It Could Have ‘Better Anticipated’ CBD Application Bottleneck

In a report to a forthcoming board meeting, UK FSA policy head Rebecca Sudworth acknowledges that the agency could have “better anticipated” the surge in cannabidiol applications received just before the 31 March 2021 deadline.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS152415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel